Aigen Investment Management’s Royalty Pharma RPRX Stock Holding History

Aigen Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-35,411	Closed	-$1.25M	–	919
2025 Q3	$1.25M	Buy	+35,411	New	+$1.28M	0.19%	153
2024 Q1	–	Sell	-15,833	Closed	-$445K	–	965
2023 Q4	$445K	Sell	15,833 -2,110	-12%	-$58K	0.08%	367
2023 Q3	$487K	Sell	17,943 -14,105	-44%	-$419K	0.09%	365
2023 Q2	$985K	Buy	+32,048	New	+$1.09M	0.15%	204
2021 Q4	–	Sell	-32,301	Closed	-$1.17M	–	1163
2021 Q3	$1.17M	Buy	+32,301	New	+$1.26M	0.22%	130

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aigen Investment Management's RPRX Position: Q4 2025 in Review

Aigen Investment Management sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 35,411 shares — an estimated $1.25M sold.

Aigen Investment Management first reported a position in RPRX in Q3 2021 and held it in 5 quarters. The position peaked at $1.25M in Q3 2025. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

Aigen Investment Management reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
Aigen Investment Management sold 35,411 Royalty Pharma shares in Q4 2025, an estimated $1.25M.
Aigen Investment Management first reported a position in Royalty Pharma in Q3 2021 and held it in 5 quarters.
Aigen Investment Management's Royalty Pharma position peaked at $1.25M in Q3 2025.
540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Aigen Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.